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Characterisation of estrogen receptor alpha (ERα)
expression in breast cancer cells and effect of drug
treatment using targeted nanoparticles and SERS†
Anastasia Kapara, a,b Valerie G. Brunton, b Duncan Graham a and
Karen Faulds *a
The detection and identification of estrogen receptor alpha (ERα), one of the main biomarkers in breast
cancer, is crucial for the clinical diagnosis and therapy of the disease. Here, we use a non-destructive
approach for detecting and localising ERα expression at the single cell level using surface enhanced
Raman spectroscopy (SERS) combined with functionalised gold nanoparticles (AuNPs). Antibody functio-
nalised nanotags (ERα-AuNPs) showed excellent biocompatibility and enabled the spatial and temporal
understanding of ERα location in breast cancer cell lines with different ERα expression status. Additionally,
we developed an approach based on the percentage area of SERS response to qualitatively measure
expression level in ERα positive (ERα+) breast cancer cells. Specifically, the calculation of relative SERS
response demonstrated that MCF-7 cells (ERα+) exhibited higher nanotag accumulation resulting in a 4.2-
times increase in SERS signal area in comparison to SKBR-3 cells (ERα−). These results confirmed the
strong targeting effect of ERα-AuNPs towards the ERα receptor. The functionalised ERα-AuNP nanotags
were also used to investigate the activity of fulvestrant, the first-in-class approved selective estrogen
receptor degrader (SERD). SERS mapping confirmed that ERα degradation occurred after fulvestrant treat-
ment since a weaker SERS signal, and hence accumulation of nanotags, was observed in MCF-7 cells
treated with fulvestrant. Most importantly, a correlation coefficient of 0.9 between the SERS response and
the ERα expression level, obtained by western blot, was calculated. These results confirmed the strong
relationship between the two approaches and open up the possibilities of using SERS as a tool for the
estimation of ERα expression levels, without the requirement of destructive and time-consuming tech-
niques. Therefore, the potential of using SERS as a rapid and sensitive method to understand the activity
of SERDs in breast cancer is demonstrated.
Introduction
Breast cancer is a major disease and the leading cause of onco-
logic mortality and morbidity among women worldwide.1,2 In
2018 there were over 2 million new cases of breast cancer
representing about 25 per cent of all cancers in women.
Incidence rates vary widely across the world, from 27 per
100000 in Middle Africa and Eastern Asia to 92 per 100000 in
Northern America.1 Current statistics also suggest than one in
eight women will develop breast cancer at some point in their
lifetime and more than 71 000 new cases are expected to be
diagnosed by 2035 in the UK.3 Approximately 75% of primary
breast tumours are diagnosed as being positive for a hormone
receptor, which can either be progesterone or estrogen recep-
tor alpha (ERα).4 ERα is a ligand-activated transcription factor,
which regulates the expression of sequences containing
specific hormone response elements responsible for body
functions in the reproductive system,5 immune system,6
bones7 and brain.8 In the UK, the phenotype of around three-
quarters of all breast cancers is characterised by the presence
of ERα.3,9,10 Therefore, ERα is a key receptor biomarker whose
status plays a pivotal role in the classification of breast cancer
subtypes, since its overexpression is related to increased pro-
liferation and metastasis in breast cancer11 which makes it an
important marker for prediction of the likelihood of a patient
developing metastatic disease.12 Therefore, the accurate assess-
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ment of ERα status is essential for diagnosis and treatment
decision making for breast cancer patients.
Currently, the most commonly used methods for assessing
and characterising ERα in human breast cancer cell lines are
immunofluorescence13,14 western blotting15 and reverse tran-
scription polymerase chain reaction (RT-PCR).16 Although
these methods can be useful for measuring the ERα
expression, there are still technical limitations as these
approaches are destructive, require processed/fixed
samples17,18 and are not suitable for use in vivo.
Immunofluorescence uses fluorescent dyes which usually have
high background signals19 and limited multiplexing capabili-
ties. Additionally, western blot and RT-PCR involve time-con-
suming experimental steps which require cell lysis and cellular
subfractionation.20,21
Surface-enhanced Raman spectroscopy (SERS) has attracted
considerable interest as a non-invasive optical technique with
unique advantages, such as narrow spectral bands that
increase the multiplexing capabilities, high sensitivity, selecti-
vity and specificity.22–24 Brolo et al. focused on quantitatively
detecting single molecules based on SERS signal intensity.25
Additionally, Schultz et al. showed that SERS can be used to
distinguish specific to non-specific nanoparticle receptor
binding.26 Therefore, it is clear that SERS is a powerful
method for the detection of single molecules and enables the
spatial and temporal understanding of where specific mole-
cules are located at a single cell level. SERS nanotags have
been successfully synthesised for various bioanalytical
measurements of cancer cells27,28 including breast cancer.29–31
The design of these SERS nanotags usually involves attaching
Raman reporters to the surface of gold (Au) or silver (Ag) nano-
particles (NPs) and functionalising with a specific targeting
biomolecule, such as monoclonal antibodies, drugs or DNA
sequences.32 Poly-ethylene glycol (PEG) can also be attached to
the nanoparticle surface to avoid dissociation of the functiona-
lised biomolecules, decrease the toxic effects,33 reduce non-
specific cellular internalisation,34 facilitate longer circulation
time in biological fluids35 and reduce aggregation of nanotags
in biological solutions.36 These nanotags can be introduced to
unprocessed samples and they can be used for a range of
applications including in vitro, ex vivo and in vivo measure-
ments using SERS. These advantages make SERS a powerful
bioanalytical tool for early tumour identification and
characterisation.
Here, anti-ERα antibody conjugated AuNPs were developed
for characterising and distinguishing breast cancer cells with
different ERα statuses, using image evaluation of the SERS
response. In parallel, we were able to investigate the activity of
fulvestrant, a commercially available ERα degrader in breast
cancer. To our knowledge, this is the first study where the
assessment of the SERS response per cell has been utilised to
characterise the ERα cancer phenotype at a single cell level
and inform about fulvestrant drug activity. This is a first step
towards using SERS for both diagnosis and investigation of the
efficacy of selective estrogen receptor degrader (SERD) drugs in
breast cancer. This has a potential future use in personalised
clinical approaches where patient derived samples could be
screened for assessing the medication activity to avoid drug re-
sistance outcomes.
Results and discussion
Nanoparticle synthesis and characterisation of ERα-AuNPs
SERS nanotags
Bare AuNPs were synthesised by standard citrate reduction of
gold.37 The functionalisation, characterisation and stability of
ERα-AuNPs SERS nanotags have been previously reported by
our group.38 Briefly, anti-ERα antibody was attached to the
AuNP gold surface via carbodiimide crosslinking chemistry.
The coupling chemistry was achieved after the attachment of
1,2-bis(4-pyridyl) ethylene (BPE) Raman reporter to the AuNPs
surface. The nanotags did not demonstrate any aggregation
and maintained their strong and characteristic SERS signal.38
Characterisation of breast cancer cells and effects of SERS
nanotags on cell viability
To validate the ability of SERS nanotags to identify and dis-
tinguish between breast cancer cells with different ERα status,
two breast cancer cell lines, ERα-positive MCF-7 cells and
ERα-negative SKBR-3 cells were chosen. To confirm the ERα
expression level in each cell line before SERS experiments were
carried out, western blots were performed. Western blot data
showed that the ERα protein had detectable expression levels
only in the MCF-7 cells and not in the SKBR-3 cells (ESI,
Fig. S1†). Immunofluorescent labelling of ERα also showed
that ERα was highly expressed in MCF-7 cells, in contrast to
SKBR-3 cells where there was no detectable ERα expression
(ESI, Fig. S2†). Before introducing the ERα-AuNP nanotags into
the cells, their cytotoxicity was assessed in MCF-7 cells and
SKBR-3 cells. 60 pM of nanotags, with and without antibody
bioconjugation, were incubated with the cells for 2 h before
the measurement of cell viability. The viability in MCF-7 cells
treated with ERα-AuNP nanotags was over 97%. There was a
small reduction in viability when MCF-7 cells were treated with
AuNPs functionalised with the BPE Raman reporter alone
(96% cell viability). Finally, the lowest viability was observed
when the cells were treated with bare AuNPs (85% cell viabi-
lity) (ESI, Fig. S3†). Similarly, SKBR-3 cells treated with
ERα-AuNPs exhibited 99% viability in contrast to PEGylated
BPE-AuNPs (94% cell viability) and BPE-AuNPs (81% cell viabi-
lity) (ESI, Fig. S4†). These results indicated that the ERα-AuNP
nanotags showed good biocompatibility and did not cause any
detectable cell toxicity. Therefore, ERα-AuNPs can be used as
an ERα targeting nanotags in live cells without affecting cell
viability.
Identification and characterisation of ERα positive breast
cancer cells using SERS
To characterise the breast cancer cell phenotype based on the
ERα expression, MCF-7 cells and SKBR-3 cells were incubated
with the ERα-AuNP nanotags under the same conditions (60
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pM, 2 h). SERS mapping of the cells after incubation with the
nanotags showed that the ERα-AuNP nanotags accumulated
more in MCF-7 cells compared to SKBR-3 cells (Fig. 1A).
Additionally, the average SERS signal from ten cells, in three
independent biological replicates, showed that MCF-7 cells
had a higher SERS intensity from the nanotags compared to
SKBR-3 cells (Fig. 1B). Specifically, the average SERS intensity
of the BPE peak at 1610 cm−1 was statistically significantly
higher in MCF-7 cells compared to SKBR-3 cells (4.5-times
higher) (Fig. 1C). Therefore, the greater SERS signal in MCF-7
cells confirmed that ERα-AuNPs specifically interacted with
the ERα receptor for their cellular uptake. In contrast, the low
uptake of ERα-AuNP nanotags in SKBR-3 cells was probably
due to non-specific interactions. This non-specific interaction
was expected to be caused by the EPR effect i.e. by non-recep-
tor-based uptake mechanisms. These data agree with our pre-
vious work where we found that ERα-AuNPs enter MCF-7 cells
using an ERα receptor-mediated endocytosis process.38 To
further investigate the location of the nanotags within the
cells, 3D SERS mapping experiments were performed through-
out the whole cell depth (30 μm in total) (ESI, Fig. S5†). The
location of the nanotags was found by creating a false colour
image using the Windows-based Raman Environment
(WiRE™ – Renishaw plc) 4.4 software package on a Renishaw
InVia microspectrometer. Direct classical least square analysis
(DCLS) was used to match the cell spectra with the reference
spectrum of BPE Raman reporter, which corresponded to
ERα-AuNP nanotags. The minimum and maximum look up
table (LUT) thresholds were set to exclude any poorly correlat-
ing or noisy spectra (min = 0.4). The 3D Raman mapping
waterfall plot of average SERS spectra at different z-axis points
treated with ERα-AuNPs showed that that the SERS signal in
MCF-7 comes from within the cells rather than the surface
(ESI, Fig. S6†). These data agree with previous 3D SERS
mapping performed from our group in MCF-7 cells treated
with the nanotags.38 The series of SERS spectra detected from
z-steps in the cell volume confirmed that the nanotags were
concentrated in certain intracellular locations, suggesting the
presence of ERα within MCF-7 cells.
SERS was found to be more effective to estimate ERα
expression and localisation in comparison to the widely used
immunofluorescence. Specifically, here we performed both
techniques for the characterisation of ERα positive breast
cancer cells (ESI, Fig. S2†). Immunofluorescence was found to
be a highly laborious technique that involved the fixation, per-
meabilisation and blocking of the cells before incubation with
the primary and secondary antibodies. SERS avoided all these
steps by being a quick, non-destructive technique that required
only a primary antibody for the characterisation of MCF-7
cells. Overall, immunofluorescence staining took 24 h whereas
SERS took only 2 hours for the slide development. This clearly
demonstrates that SERS and ERα-AuNPs nanotags can be uti-
lised to investigate the ERα status of breast cancer cells, as well
as to distinguish ERα positive breast cancer cells from ERα
negative breast cancer cells with high sensitivity and
specificity.
Calculation of relative SERS response value in breast cancer
cells
A method for the estimation of the relative uptake of SERS
nanotags into cells has been previously described by our
group.38 Briefly, we have developed a direct, rapid and non-
destructive method to calculate the percentage of SERS respon-
sive pixels per cell and provide an indication of the relative
value for the uptake of nanotags per condition. Although, this
is not a direct quantification of the total number of nanotags
in the cells, it is an effective way to estimate the SERS signal
per cell area, quantify the number of pixels that correspond to
the SERS signal, identify the localisation of the nanotags, and
allowing relative comparison between different samples. Here,
the evaluation of SERS response in cells showed that there was
a statistically significant higher percentage area of SERS
response in MCF-7 cells in comparison to SKBR-3 cells (4.2-
Fig. 1 ERα-AuNP nanotags accumulation in MCF-7 cells compared to
SKBR-3 cells. (A) SERS map of MCF-7 cells and SKBR-3 cells incubated
with 60 pM ERα-AuNP nanotags for 2 h at 37 °C. Images were generated
with a 50× magnification NIR APO Nikon water immersion objective
with 1.0 NA, laser power of 1.2 mW (10% power) at the sample, from a
HeNe 633 nm excitation source with a 0.1 s acquisition time per point,
and a 1200 L mm−1 grating in high confocality mode. The false colour
images representing the location of ERα-AuNPs were generated using
the Windows-based Raman Environment (WiRE™ – Renishaw plc) 4.4
software package on a Renishaw InVia microspectrometer and direct
classical least square analysis (DCLS) based on a BPE Raman reporter
reference spectrum. The minimum and maximum look up table (LUT)
thresholds were set to exclude any poorly correlating or noisy spectra
(min = 0.4). Results are representative of 3 independent experiments.
Scale bars = 10 μm. (B) Average SERS spectra of MCF-7 cells (black) and
SKBR-3 cells (grey) incubated with ERα-AuNPs (60 pM for 2 h). Average
SERS intensity was calculated from ten cells in three separate experi-
ments. (C) Average SERS intensity at 1610 cm−1 (most intense peak of
the BPE Raman reporter). The average of ten samples from three inde-
pendent biological replicates is shown. Error bars presented as mean ±
S.D. * Significant difference (p < 0.05) in a Student’s t test.
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times higher) (Fig. 2). The different phenotype of MCF-7 cells
and SKBR-3 cells was also confirmed using the average SERS
intensity of the peak at 1610 cm−1 (Fig. 1C). However, since
the average signal can be influenced by the formation of aggre-
gates in the cell area, the evaluation of SERS response using
pixel counting is considered more informative since it takes
into account only the location of the nanoparticles’ signal and
it is not influenced by SERS intensity. Additionally, it was
observed that the percentage of SERS response from targeted
ERα-AuNP nanotags was 3.8-times higher compared to untar-
geted PEG5000-AuNPs (no antibody attached) in MCF-7 cells
(1.68% and 0.44% respectively). In contrast, there was no stat-
istically significant difference between the ERα-AuNPs and
PEG5000-AuNPs (0.4% and 0.6% respectively) in the SKBR-3
cells (Fig. 2) suggesting a non-specific interaction. These
results confirmed the strong targeting effect of the ERα-AuNP
nanotags towards the ERα positive MCF-7 cells in comparison
to the negative SKBR-3 cells, whilst the nanotags without the
antibody on their surface had no targeting effect in both cell
lines. This is an important finding since it demonstrates that
the targeted nanotags have much greater uptake compared to
non-specific uptake by the enhanced permeability and reten-
tion (EPR) effect.
Assessment of fulvestrant activity using SERS in breast cancer
Approximately 75% of primary breast tumours in women test
positive for a hormone receptor.3 The hormone receptor can
be either progesterone (PR) and/or estrogen receptor alpha
(ERα).3 In the UK, the phenotype of around three-quarters of
all breast cancers is characterised by the presence of ERα.4,5
Currently, both ERα and PR positive patients are treated with
the same hormonal therapy.6 Therefore, the assessment of the
drug activity of an anti-ERα treatment will also be beneficial
for patients with PR positive breast cancer. Fulvestrant is the
first commercially available drug that is a selective estrogen
receptor degrader (SERD).39,40 SERD is a class of drugs that
bind to the ERα receptor and causes its degradation and, thus,
its down regulation.41 However, like all hormonal therapy
drugs, fulvestrant is known to have side effects, such as
decreased white blood cells, abnormal liver function and
increased risk of infections.40,42 The ability to understand the
efficacy of fulvestrant is important for improving the way that
the drug is used clinically. Therefore, we used our SERS
approach to determine the activity of fulvestrant in MCF-7
cells. Specifically, MCF-7 cells were treated with increasing
concentrations of fulvestrant (0.01 μM to 1 μM) for 24 h before
lysing and western blot analysis. The results showed that
increasing the concentration of fulvestrant decreased the
expression of the ERα protein in MCF-7 cells compared to
DMSO (vehicle control) treated cells (Fig. 3A and B). Since 500
nM and 1 μM fulvestrant resulted in the lowest ERα expression,
these concentrations were used for the SERS experiments.
Specifically, for SERS mapping, MCF-7 cells were treated with
DMSO, 500 nM and 1 μM fulvestrant for 24 h before the
addition of ERα-AuNPs nanotags (60 pM) for 2 h.
The SERS results clearly correlated with the western blot
experiment since a decreased accumulation of nanotags was
observed after treatment with 500 nM fulvestrant compared to
DMSO (vehicle control). Additionally, a further reduction in
the nanotag accumulation was observed with 1 μM fulvestrant
in comparison to 500 nM fulvestrant treatment (Fig. 3C). The
calculation of the area of SERS response in MCF-7 cells
showed that there was a statistically significant decrease (5.4-
times reduction) between the MCF-7 cells treated with 1%
DMSO (vehicle control) and the ones treated with 1 μM fulves-
trant (Fig. 3D). Moreover, 500 nM fulvestrant treatment led to
a 2.3 times decrease in the area of SERS response compared to
1% DMSO. These results clearly demonstrate that the amount
of targeted nanotag uptake by cells, and the resultant SERS
response, correlates with ERα expression levels and is a poten-
tially powerful method for understanding the activity of SERD
drugs by providing real time measurements of activity at the
single cell level. Most importantly, it was shown that the SERS
response and the ERα quantification data from the western
blot had a very strong relationship (Fig. 3E). Specifically, the
correlation coefficient between the normalised data from SERS
and western blot was found to be 0.9 which indicates positive
linear correlation between the two variables.43 Therefore, this
correlation opens up the potential of using SERS as a tool to
Fig. 2 Calculation of relative SERS response showed statistically signifi-
cant higher uptake in MCF-7 cells than SKBR-3 cells treated with
ERα-AuNPs (60 nM, 2 h) and PEG5000-AuNPs (60 nM, 2 h). The calcu-
lations suggest that the binding and internalisation of the ERα-AuNPs is
more efficient at targeting MCF-7 cells. Percentage of ERα-AuNPs area
in MCF-7 cells estimated using the Fiji image processing package by cal-
culating the red pixel number, corresponding to the ERα-AuNPs, and
the cell area that was mapped. This was an estimation of the percentage
of SERS responsive pixels per cell and not a quantification of the total
number of nanoparticles in the cells. The average of ten samples from
three independent biological replicates is shown. Error bars presented
as mean ± S.D. *Significant difference (p < 0.05) in a one-way analysis of
variance (ANOVA) with post-hoc Tukey’s test.
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predict ERα protein expression levels without the need for
destructive and time-consuming western blot analysis.
Conclusions
A novel method based on the assessment of SERS response
was successfully demonstrated for characterising ERα-positive
breast cancer cells. This provided a method to follow the
effects of a drug treatment in breast cancer cells using the
ERα-AuNP nanotags. SERS is a non-destructive method that
has the advantages of being rapid with high sensitivity and
specificity for targeting ERα overexpression at a single breast
cancer cell level. However, most importantly, SERS was used
for both characterising the breast cancer cell phenotype as well
as understanding fulvestrant activity, a SERD treatment for
ERα positive breast cancer. The calculation of SERS response
confirmed higher nanotag accumulation in ERα-positive cells
(MCF-7) compared to ERα-negative cells (SKBR-3). The obvious
differences in SERS intensity detected from the two different
breast cancer cell lines confirmed the specificity and strong
targeting effect of ERα-AuNP nanotags against ERα. These
results were more effective in comparison to other experi-
mental approaches that use fluorescence for ERα analysis
since they are usually related to high background signals, time
consuming experiments, and use of a primary and a secondary
antibody for the imaging analysis. The accurate evaluation of
the percentage area of SERS response provided an understand-
ing of ERα expression levels before and after fulvestrant treat-
ment. The SERS response calculations verified the reduction
in ERα expression levels after treatment with the ERα degrader,
fulvestrant. Above all, a direct correlation between the SERS
response and western blot experiments, which quantified ERα
expression, was observed. This work, therefore, highlights that
AuNP based SERS imaging could be of great importance for
diagnostic accuracy, involving molecular characterisation and
intracellular imaging, and understanding of drug activity into
different cell types. Future prospective studies may also involve
using SERS as a complementary approach for monitoring
patient derived breast cancer cells for evaluating the drug
efficacy and propose a personalised drug treatment to avoid
drug resistance outcomes.
Experimental
Materials
Anti-estrogen receptor alpha antibody (ab16660) was pur-
chased from Abcam (330 Cambridge Science Park, Cambridge,
CB4 0FL, UK). Anti-mouse IgG HRP-linked antibody (7076S)
and anti-rabbit IgG HRP-linked antibody (7074S) were pur-
chased from Cell Signalling Technology (Hamilton House,
Mabledon Place, London, WC1H 9BB, UK). Sodium tetrachlor-
oaurate dihydrate, (N-(3-Dimethylaminopropyl)-N′-ethylcarbo-
diimide hydrochloride) (EDC), N-hydroxysulfosuccinimide
sodium salt (NHS), poly (ethylene glycol) 2-mercaptoethyl
ether acetic acid (HS-PEG5000-COOH), 1,2-bis(4-pyridyl) ethyl-
ene (BPE), 4-(2-hydroxyethyl)-1-piperazineethancesulfonic acid
(HEPES), and 2-(N-morpholino) ethanesulfonic acid (MES)
were obtained from Sigma-Aldrich Ltd (The Old Brickyard,
New Road, Gillingham, Dorset, SP8 4XT, UK). LIVE/DEAD
Viability/Cytotoxicity Assay Kit was purchased from
ThermoFisher Scientific (3 Fountain Dr, Inchinnan, Renfrew
PA4 9RF, UK). Milli-Q deionized water was used after purifi-
Fig. 3 ERα-AuNP nanotags can be used to assess fulvestrant activity in
MCF-7 cells. (A) ERα expression in MCF-7 cells treated with different
concentrations of fulvestrant (0.01 μM to 1 μM) for 24 h. Cell lysates
were prepared from breast cancer cell lines and western blot analysis
carried out using a secondary antibody to ERα, β-actin was used as a
loading control. (B) Quantitative analysis of the relative expression of
ERα and GAPDH (housekeeping protein). The results are expressed as
means ± SD of triplicate determinations. P < 0.001 versus 1% DMSO
(vesicle control). Statistical analysis was conducted using one-way
ANOVA. (C) SERS map of MCF-7 cells treated with fulvestrant (500 nM
and 1 μM) for 24 h and ERα-AuNP nanotags (60 pM, 2 h). The images
were generated with a 20× magnification NIR APO Nikon objective, laser
power of 1.2 mW (10% power), from a HeNe 633 nm excitation source
with a 0.1 s acquisition time per point, and a 1200 L mm−1 grating in
high confocality mode. The false colour images representing the
location of ERα-AuNPs were generated using the Windows-based
Raman Environment (WiRE™ – Renishaw plc) 4.4 software package on a
Renishaw InVia microspectrometer and direct classical least square ana-
lysis (DCLS) based on the BPE Raman reporter reference spectrum. The
minimum and maximum look up table (LUT) thresholds were set to
exclude any poorly correlating or noisy spectra (min = 0.4) Scale bars =
20 μm. (D) Area of SERS response in MCF-7 cells treated with fulvestrant
(500 nM and 1 μM) for 24 h and then with ERα-AuNP nanotags (60 pM)
for 2 h. The average of ten samples from three independent biological
replicates is shown. Error bars presented as mean ± S.D. (E) Correlation
of normalised area of SERS response and normalised relative expression
of ERα in untreated MCF-7 cells and MCF-7 cells treated with fulvestrant
(500 nM and 1 μM) for 24 h.
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cation by Milli-Q purification system. All glassware was
cleaned in aqua regia (3 HCl : 1 HNO3).
Nanoparticle synthesis and functionalisation
Citrate reduced gold (Au) nanoparticles were synthesised
according to the Turkevich, Stevenson and Hillier method.12
Briefly, sodium tetrachloroaurate dihydrate solution (10 mL,
15 mM) in 490 mL deionised water was boiled under continu-
ous stirring. Sodium citrate tribasic dihydrate solution
(7.5 mL, 26 mM) was then added. The mixture was boiled with
stirring for 1 h. Differential light scanning analysis (DLS) of
AuNPs showed that the average size of AuNPs was 52.5 ±
0.79 nm with a narrow size distribution. Scanning electron
microscopy (SEM) of AuNPs agreed with the DLS measure-
ments and confirmed that AuNPs had a spherical shape with a
diameter distribution ranging from 40 to 50 nm. For the
carbodiimide crosslinking conjugation, 74 μL of EDC solution
(1 mg mL−1 in 10 mM MES, pH 6.0) was mixed with 40 μL of
HS-PEG5000-COOH (12.5 μM in dH20) followed by the addition
of 217 μL of NHS (1 mg mL−1 in 10 mM MES, pH 6.0) and
20 μL of anti-ERα antibody (2.5 mg mL−1 in dH20). The final
solution was incubated in 40 μL of 10 mM HEPES buffer pH
7.0 on a shaker plate for 18 h at room temperature. 10 μL of
1,2-bis(4-pyridyl) ethylene (BPE) (0.1 μM) was added to bare
AuNPs (0.03 nM, 990 μL) and the solution was incubated on
the shaker plate for 30 min followed by centrifugation at 6000
rpm for 20 min. The solution of EDC-NHS-PEG5000-mAb was
added dropwise to the pelleted BPE-AuNPs. The nanotags were
incubated on a shaker plate for 3 h. Excess free protein was
removed by centrifugation at 8000 rcf for 10 min and was used
for protein concentration estimation analysis.
Nanoparticle characterisation
Extinction spectra were measured using an Agilent Cary 60
UV-Visible (UV-vis) spectrophotometer with Win UV scan
V.2.00 software. The instrument was allowed to equilibrate to
RT before using poly(methyl methacrylate) (PMMA) disposable
plastic micro cuvettes with 500 μL sample volumes to scan
wavelengths from 300–800 nm. Where required, samples were
diluted to give extinction values of less than one to adhere to
the Beer–Lambert law, to allow calculation of the concen-
tration of AuNPs. Dynamic light scattering (DLS) and
ζ-potential were measured using a Malvern Zetasizer Nano ZS
with 800 μL of the sample in a PMMA disposable micro
cuvette with Zetasizer μV and APS v.6.20 software. Polystyrene
latex beads (40 nm) were used as a standard to validate the
calibration of the system before running samples.
Measurements were taken in triplicate. A scanning electron
microscope (SEM) FEI Quanta 250 FEG-ESEM was used to
image at an accelerating voltage of 30 kV and typically a spot
size of 4 was selected, and an Everhart–Thornley detector col-
lected secondary electrons. For the solution measurements of
the nanotags, SERS analysis was carried out on a Snowy Range
CBEx 2.0 handheld Raman spectrometer (Snowy Range
Instruments, Laramie WY USA) equipped with a 638 nm laser
with a maximum laser power of 30 mW. Samples were de-
posited in glass vials for interrogation. The sample volumes
were 600 μL and spectra were collected using 100% laser power
at the sample with a 0.05 s accumulation time. The software
used to acquire spectra was peak 1.1.112. Resulting spectra
were baseline corrected in Matlab 2014b.44
Cell culture conditions
MCF-7 cells (ATCC® HTB-22™) and SKBR-3 cells (ATCC®
HTB-30™) were obtained from American Type Culture
Collection (ATCC) (Queens Road, Teddington, Middlesex,
TW11 0LY, UK). Cells were maintained between passage
number 5 and 30. The human breast cancer cells were cultured
in Rosewell Park Memorial Institute medium (RPMI 1640) sup-
plemented with 1% penicillin/streptomycin (10 000 units per
mL), 1% fungizone, and 10% heat-inactivated fetal bovine
serum (FBS). Cells were incubated under humidified 37 °C and
5% CO2 in a humidified incubator. Cells at a confluence of ca.
90% growing in a T175 flask were trypsinised and re-sus-
pended in medium to give a concentration of ca. 1 × 106 cells
per mL.
ERα-AuNPs and fulvestrant treatment
MCF-7 cells (1 × 106 cells per mL) were seeded onto sterile
22 mm square glass coverslips with culture medium.
ERα-AuNP nanotags (60 pM, 2 h) were incubated with the cells
at 37 °C, 5% CO2 in a humidified incubator. The coverslips
were washed in PBS three times and fixed in 4% paraformalde-
hyde for 15 min. For assessing fulvestrant activity using SERS,
MCF-7 cells (1 × 106 cells per mL) were seeded onto sterile
22 mm square glass coverslips and treated with 1% DMSO
(control) or with fulvestrant (500 nM and 1 μM) for 24 h.
ERα-AuNPs (60 pM) were then added to the cells for 2 h. The
coverslips were washed in PBS three times and fixed in 4% par-
aformaldehyde for 15 min. The fixed cells were washed in PBS
and dH20 and left to air dry before mounting on a standard
glass microscope slide for SERS imaging.
Western blot experiments after fulvestrant treatment
The cells (1 × 106 per mL) were plated in 10 cm diameter
dishes with 10 mL of RPMI and left for 24 h before fulvestrant
was added with increasing concentrations (0.01 μM to 1 μM)
for 24 h. The next day the media was aspirated from the
culture. The cells were washed in ice cold PBS twice and were
lysed with 200 μL of ice cold RIPA buffer (#10017003, Thermo
Fisher), containing a tablet of protease and phosphatase
inhibitor (#A32959, Pierce). The cells were immediately
scraped off the plate and their extracts were transferred to a
microcentrifuge tube. The samples were kept on ice for 15 min
and were centrifuged at 14 000 rpm for 15 min at 4 °C. The cell
lysate supernatant was then used for protein quantification
using the BCA assay. The cell lysate samples (20 μL, 1 mg
mL−1) were diluted with 5× SDS loading buffer, heated to
95 °C for 5 min and microcentrifuged for 5 min at RT. 20 μL of
the denatured cell lysate was loaded into a 12% gel (Mini
Protean TGX stain free Pre-cast gels, #456-8085, Bio-Rad) and
run at 140 V for 40 min. A prestained molecular weight marker
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(5 μL) was also loaded into the gel to determine the molecular
weights of the proteins of interest. The gel was electrotrans-
ferred to a 0.2 μm nitrocellulose membrane (#170-4159, Bio-
Rad) with the BioRad TransBlot Turbo Transfer System using
the Midi gel 10 min transfer setting. The membrane was
blocked with 5% BSA blocking buffer for 1 h at room tempera-
ture. After blocking, the membrane was incubated at 4 °C over-
night whilst rocking with the appropriate primary antibody
diluted in 5 mL 5% w/v BSA, 1× TBS, 0.1% Tween 20. The next
day the membrane was washed three times for 5 min each
with 15 mL of TBST buffer (1.5% Tween 20 in 1× TBS). The
membrane was incubated with the appropriate secondary anti-
body in 10 ml of 5% BSA blocking buffer with gentle agitation
for 1 h at room temperature and was washed three times for
5 min each with 15 mL of TBST buffer. For the detection of the
proteins, the membrane was incubated with 1 : 1 of Pierce™
ECL western blotting substrate (#32106, Thermo fisher) for
1 min. Finally, a Bio-Rad ChemiDoc MP Imaging System-
Universal Hood III with Image Lab V.4.1 software was used to
image and quantify the protein levels on the membrane.
Fluorescence microscopy
MCF-7 cells were seeded onto a 6-well plate (1 × 106 cells per
mL) and incubated at 37 °C and 5% CO2 for 24 h. After 24 h
the cells were washed in PBS three times and fixed in 4% par-
aformaldehyde for 15 min at room temperature. The fixed cells
were permeabilised with 0.1% Triton X-100 in PBS for 10 min.
The cells were then washed in PBS three times for 5 min.
Then, the cells were blocked with 1% BSA, 22.52 mg mL−1
glycine in 0.1% PBS-Tween for 1 h. The cells were then incu-
bated with the diluted antibody (ab16660) (1/200 dilution in
1% BSA in PBS-Tween) overnight at 4 °C. The cells were then
washed in PBS three times for 5 min. Finally, the cells were
incubated with the secondary antibody (Alexa Fluor® 647) (1/
200 dilution in 1% BSA) for 1 h at room temperature in the
dark. The cells were then washed in PBS three times for 5 min
and 1 μg mL−1 of DAPI (DNA stain) was added for 10 min. The
images were generated using a Leica Microsystems TCS SP8
with continuous wave visible lasers and Leica DMi8 inverted
microscope and DFC 7000T and TL LED cameras. The software
was Leica Application Suite X V.3.1.5.16308 to carry out live/
dead studies a 63× magnification HC PL APO water objective
with a 1.2 NA was used. Intensity and area of fluorescence were
measured using Image J (National Institute of Health (NIH))
software with Fiji plug-in to measure the area of fluorescent
stain.45
Solution measurements of ERα-AuNPs
The SERS nanotags were assessed by SERS analysis which was
carried out on a Snowy Range CBEx 2.0 handheld Raman
spectrometer (Snowy Range Instruments, Laramie WY USA)
equipped with a 638 nm laser with a maximum laser power of
30 mW. Samples were deposited in glass vials for interrog-
ation. The sample volume was 600 μL and spectra were col-
lected using 100% laser power at the sample with a 0.05 s
accumulation time. The software used to acquire spectra was
peak 1.1.112. Resulting spectra were baseline corrected in
Matlab 2014b typically using polynomial smoothing of 1 × 107
and asymmetry of 1 × 10−3.44
Raman cell mapping
The intracellular uptake of the nanotags was examined using
Raman cell mapping. A Renishaw InVia Raman confocal
microscope was used to create initial depth profiles, to estab-
lish the focal plane of the fixed cells in correlation with the
white light images. The MCF-7 cells and SKBR-3 cells that were
imaged had a typical cell size of around 20–25 microns. Cells
with similar height characteristics were selected for the 3D
SERS mapping experiments to allow more direct volume com-
parisons. Therefore, cells that were mapped were all approxi-
mately 15 μm in height. Before each map, the cells were ana-
lysed under the microscope, and the z = 0 was set accordingly.
3D SERS maps were collected in edge Streamline HR high con-
focality mode at 1 μm resolution in the X and Y directions and
3 μm between Z-stacks. A 50× magnification NIR APO Nikon
water immersion objective with a 1.0 NA was used on the
samples at a laser power of 1.2 mW (10% power) at the
sample, from a HeNe 633 nm excitation source with a 0.1 s
acquisition time per point, and a 1200 L mm−1 grating in high
confocality mode. Windows-based Raman Environment
(WiRE™ – Renishaw plc) 4.4 software package was used to pre-
process the data for cosmic ray removal and baseline subtrac-
tion. The image was generated using direct classical least
square analysis (DCLS) based on BPE or PPY reference spec-
trum. Therefore, the false colour was generated only when
there was a good spectral fit between the reference and the col-
lected spectra. All SERS experiments contained n = 10 biologi-
cal replicates and experiments were in triplicate.
Calculation of relative SERS response value in breast cancer
cells
The evaluation of SERS response in breast cancer cells has
been previously described by our group.38 Briefly, the spectra
from the SERS cell mapping analysis were baselined and
cosmic rays were removed using the Windows-based Raman
Environment (WiRE™ – Renishaw plc) 4.4 software package.
The images were generated using direct classical least square
analysis (DCLS) based on the Raman reporter reference spec-
trum. DCLS fitted the unknown data (collected during cell
mapping) to a linear combination of the specified component
spectrum (Raman reporter reference spectrum). If there was a
good spectral fit between the Raman reporter reference and
the collected spectra a gradient red false colour was assigned.
Associated with each false colour image was a look up table
(LUT). The minimum and maximum values of the LUT indi-
cates the degree of spectral fit. Afterwards, the gradient red
false colour was converted to monochromatic red colour,
without affecting the intracellular SERS signal, using the
Windows-based Raman Environment (WiRE™ – Renishaw plc)
4.4 software package.
Fiji image processing package45 was used for the quantifi-
cation of the pixel numbers of ERα-AuNPs and the cell area
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after SERS mapping. Specifically, the cellular area was selected
by masking everything outside of it. The image was then
colour split to the monochromatic red channel, where only the
red pixels were present. Then, the red pixels were extracted
above 200-threshold to count only the pixels that correspond
to the nanotags and not from any cellular component. Finally,
the percentage of the red pixel area (corresponding to SERS
response) versus the full cell area was calculated. The percen-
tage of the cellular SERS signal was determined by calculating
the area of cells with SERS response divided by the surface
area.
Statistical analysis
Statistical analysis was carried out on GraphPad Prism 8.1.2
(GraphPad Software, Inc., San Diego, CA). The Student’s t-test
was used for comparison of two variables and one-way analysis
of variance (ANOVA) with post-hoc Tukey’s test for comparison
of three or more groups. Differences between groups were sig-
nificant at a P value of <0.05.
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